Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.46 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.46 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.38 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.36 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.36 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.36 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.36 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.36 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.36 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 7/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | RECQL | P46063 | 3/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10318019 | 0.95 | SLC7A5 (0.51) | SLC7A5ALOX15KDM4ERECQLHIF1A | |
| SCHEMBL2311992 | 0.95 | SLC7A5 (0.51) | SLC7A5ALOX15KDM4ERECQLHIF1A | |
| SCHEMBL3411781 | 0.95 | SLC7A5 (0.51) | SLC7A5ALOX15KDM4ERECQLHIF1A | |
| SCHEMBL8230342 | 0.86 | SLC7A5 (0.40) | SLC7A5ALOX15KDM4ERECQLHIF1A | |
| SCHEMBL3412205 | 0.86 | SLC7A5 (0.51) | SLC7A5ALOX15KDM4ERECQLHIF1A | |
| SCHEMBL12646479 | 0.85 | CA1 (0.40) | ALOX15KDM4ERECQLHIF1AHSD17B10 | |
| SCHEMBL15120465 | 0.84 | ALOX15 (0.42) | SLC7A5ALOX15KDM4ERECQLHIF1A | |
| SCHEMBL12646488 | 0.82 | LCK (0.42) | SLC7A5ALOX15KDM4ERECQLHIF1A | |
| SCHEMBL9883712 | 0.82 | LCK (0.42) | SLC7A5ALOX15KDM4ERECQLHIF1A | |
| SCHEMBL1172262 | 0.79 | CA1 (0.47) | SLC7A5ALOX15KDM4ERECQLHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1959948-B1 | LEVODOPA PRODRUG MESYLATE, COMPOSITIONS THEREOF, AND USES THEREOF | XENOPORT INC (US) | 2012-07-18 | — | — | EP | claimed |
| US-8193242-B2 | Levodopa prodrug mesylate, compositions thereof, and uses thereof | XENOPORT, INC. (US) | 2012-06-05 | — | — | US | claimed |
| US-7968597-B2 | Levodopa prodrug mesylate, compositions thereof, and uses thereof | XENOPORT, INC. (US) | 2011-06-28 | — | — | US | claimed |
| US-20110111062-A1 | LEVODOPA PRODRUG MESYLATE, COMPOSITIONS THEREOF, AND USES THEREOF | XENOPORT, INC. | 2011-05-12 | — | — | US | claimed |
| US-7893105-B2 | Levodopa prodrug mesylate, compositions thereof, and uses thereof | XENOPORT, INC. (US) | 2011-02-22 | — | — | US | claimed |
| US-20090326067-A1 | Levodopa Prodrug Mesylate, Compositions Thereof, and Uses Thereof | XENOPORT, INC. (US) | 2009-12-31 | — | — | US | claimed |
| US-7563821-B2 | Levodopa prodrug mesylate, compositions thereof, and uses thereof | XENOPORT, INC. (US) | 2009-07-21 | — | — | US | claimed |
| US-20090156679-A1 | LEVODOPA PRODRUG MESYLATE, COMPOSITIONS THEREOF, AND USES THEREOF | XENOPORT, INC. | 2009-06-18 | — | — | US | claimed |
| EP-1959948-A2 | LEVODOPA PRODRUG MESYLATE, COMPOSITIONS THEREOF, AND USES THEREOF | Xenoport, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| US-20070225366-A1 | Levodopa prodrug mesylate, compositions thereof, and uses thereof | XENOPORT, INC. | 2007-09-27 | — | — | US | claimed |
| WO-2007067495-A2 | LEVODOPA PRODRUG MESYLATE, COMPOSITIONS THEREOF, AND USES THEREOF | XENOPORT, INC. (US) | 2007-06-14 | — | — | WO | claimed |
| US-8722733-B2 | Levodopa prodrug mesylate hydrate | XENOPORT, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130184344-A1 | LEVODOPA PRODRUG MESYLATE HYDRATE | XENOPORT, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8399513-B2 | Levodopa prodrug mesylate hydrate | XENOPORT, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120296109-A1 | Levodopa Prodrugs, and Compositions and Uses Thereof | XENOPORT, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-7563821-B2 | Levodopa prodrug mesylate, compositions thereof, and uses thereof | XENOPORT, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20090156679-A1 | LEVODOPA PRODRUG MESYLATE, COMPOSITIONS THEREOF, AND USES THEREOF | XENOPORT, INC. | 2009-06-18 | — | — | US | disclosed |
| EP-1959948-A2 | LEVODOPA PRODRUG MESYLATE, COMPOSITIONS THEREOF, AND USES THEREOF | Xenoport, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070225366-A1 | Levodopa prodrug mesylate, compositions thereof, and uses thereof | XENOPORT, INC. | 2007-09-27 | — | — | US | disclosed |
| WO-2007067495-A2 | LEVODOPA PRODRUG MESYLATE, COMPOSITIONS THEREOF, AND USES THEREOF | XENOPORT, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156679-A1 | LEVODOPA PRODRUG MESYLATE, COMPOSITIONS THEREOF, AND USES THEREOF | COMT, PARK7, SNCA | HTR2A 137/4885EGFR 4020/4885ADRB2 1580/4885 |
| US-20130184344-A1 | LEVODOPA PRODRUG MESYLATE HYDRATE | PARK7, COMT, SLC6A3 | HTR2A 61/4885EGFR 4702/4885ADRB2 1009/4885 |
| US-20090326067-A1 | Levodopa Prodrug Mesylate, Compositions Thereof, and Uses Thereof | COMT, PARK7, SNCA | HTR2A 137/4885EGFR 4020/4885ADRB2 1580/4885 |
| US-20110111062-A1 | LEVODOPA PRODRUG MESYLATE, COMPOSITIONS THEREOF, AND USES THEREOF | COMT, PARK7, SNCA | HTR2A 137/4885EGFR 4020/4885ADRB2 1580/4885 |
| US-20120296109-A1 | Levodopa Prodrugs, and Compositions and Uses Thereof | COMT, PARK7, SNCA | HTR2A 200/4885EGFR 3812/4885ADRB2 1497/4885 |
| US-20070225366-A1 | Levodopa prodrug mesylate, compositions thereof, and uses thereof | COMT, PARK7, SNCA | HTR2A 137/4885EGFR 4020/4885ADRB2 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.